warfarin

Regs, robbery responses among top “pharmacy gamechangers” for 2016
Regs, robbery responses among top “pharmacy gamechangers” for 2016The issues of most concern to pharmacists, outlined at McKesson’s ideaShare 2016.
Warfarin for CKD, aspirin for TIA, and what to do about ICHAnticoagulation briefs.
USPSTF updates recommendations for aspirin useThe guidelines, which update the group's 2007 and 2009 recommendations, are published in the "Annals of Internal Medicine."
Fall-related ICH incidence in elderly on warfarinA study of nearly 32,000 aging veterans revealed the unsuspected vulnerability of this population.
ICH volume smaller with DOACs than with warfarinA study of 344 patients with anticoagulant-associated ICH found that when data were adjusted for confounding factors, warfarin use remained independently associated with larger ICH volumes.
The expanding role of direct oral anticoagulants in the management of thromboembolic disease
The expanding role of direct oral anticoagulants in the management of thromboembolic diseaseThe goal of this program for pharmacists and technicians is to review the treatment of venous thromboembolism with the class of medications known as direct oral anticoagulants.
Study: Shorter hospital stays with XareltoUS hospitals using rivaroxaban (Xarelto, Janssen Pharmaceuticals) instead of warfarin (Coumadin, Bristol-Myers Squibb) to treat patients diagnosed with a venous thromboembolism (VTE) may save nearly $2,000 per patient and shorten a patient’s hospital stay by approximately 1.5 days, according to a new study.
Pre-op anticoagulation reduces VTE risk in cancer patientsResearchers found that rates of DVT and PE were significantly lower among patients who received preoperative chemoprophylaxis than in those who did not.
Limb gangrene in cancer patients receiving warfarinVenous limb gangrene can occur in cancer patients, but the clinical picture and pathogenesis aren’t clear.
Renal function decline common in patients treated with DOACsDeterioration of renal function and an increase in related adverse events is not unusual in patients treated with direct oral anticoagulants.